In the Spotlight: Ali Al-Bazergan.
Get to know our analyst team one at a time in our new exclusive interviews
Ali joined Datamonitor Healthcare in 2013 as an analyst in the company analysis team. Aside from following a major portfolio of pharma and biotech companies, he focuses particularly on deals and M&A. We’ve put Ali in the spotlight to find out what get’s his juices flowing and why he’s excited about our new PharmaVitae 2.0 launch…
What is your background?
I did a Master’s degree at University College London in Biochemical engineering with Bioprocess Management. My time there was predominately focused on biopharmaceutical development and commercialization.
What is your role here at Datamonitor Healthcare?
I am a Senior Analyst in the company analysis team. My work to date has been focused on tracking and forecasting a portfolio of large and mid-cap companies, while being engaged in providing insight into M&A, strategic drivers, and industry trends.
Within these areas, what has been your most interesting research project?
Evolving the company analysis content has been particularly rewarding. The development of the new PVX 2.0 (company analysis platform) will lay solid foundations to bolster the portfolio further and enhance user experience and faster response times to market events. Spearheading new M&A content alongside the recent wave was extremely exciting – talk of hostile takeovers, asset swaps, and poison pills really gets your juices flowing.
What do you like most about working at Datamonitor Healthcare?
There’s ample room to innovate and influence the content to best serve our clients. As the sector faces internal and external headwinds in the market, there’s a real dedication across the Datamonitor Healthcare team to provide clients with the intelligence to navigate the best path towards taking advantage of opportunities and realizing strategic bets.
Why do you think our customers like Datamonitor Healthcare?
The company is very customer centric – in developing the new PVX 2.0 platform, many iterations in the design involved using direct feedback from long-term users in the industry. We also strive towards transparency in all of our content to allow clients to easily understand all our conclusions with the option to directly interact with all the analysts to shed even more light on a particular subject.
What do you think your greatest achievement has been since working at Datamonitor Healthcare?
It has to be building out the company portfolio – we’ve really come far with how we blend and visualize data, and alongside process improvements, we’re a lot more nimble in reacting to market catalysts with the new platform. Building out novel analysis on recent deals and M&A also provided a good opportunity to exchange my views on recent trends and acquisition strategies alongside executives on industry panels.
What are you most excited about this year in the pharmaceutical market?
I’m really interested in how further M&A can shape the industry landscape even more. Although the US has cracked down on tax inversions with the failure of AbbVie’s acquisition of Shire, more consolidation is expected in light of asset availability and cheap debt. There’s also the momentum in immuno-oncology where we’re seeing big players investing to vie for market share. With more readouts for key pipeline candidates and combinations this year, we’ll have an even better idea of which companies are better poised for promising growth in the area.
Outside work, what do you enjoy doing?
I take a few evening language classes and try to keep as active as I can – I am a keen squash player and enjoy playing for a football club based in west London.
A big thank you to Ali for taking the time to talk to us!
- If you’d like to keep up to date with what Ali is up to this year you can follow him on twitter by clicking here.
- You can also read his full bio here.
If you’re interested in seeing more of what Ali does at Datamonitor Healthcare please download some of our free pieces of content below:
Posted in Company analysis.